In this issue:
Elevated cancer risk in patients with HS
HS epidemiology, clinical presentation, pathogenesis and treatments
Is adalimumab for treatment of HS safe during the COVID-19 pandemic?
Malignancy and infection risk during adalimumab therapy in HS
Paradoxical HS in patients receiving TNF-α inhibitors
The surface microbiome of clinically unaffected skinfolds in patients with HS is similar to that seen in chronic HS lesions
Amyloidosis in HS
The biologic brodalumab shows efficacy for HS treatment
Triplet antibiotic therapy shows promise for achieving clinical remission in Hurley stage 1 HS
Please login below to download this issue (PDF)